Literature DB >> 26004160

Depressive state and chronic fatigue in multiple sclerosis and neuromyelitis optica.

Tetsuya Akaishi1, Ichiro Nakashima1, Tatsuro Misu2, Kazuo Fujihara2, Masashi Aoki1.   

Abstract

Depression and chronic fatigue are frequently present in multiple sclerosis (MS); however, the prevalence rates have not been investigated in neuromyelitis optica (NMO). Thirty-nine consecutive NMO and 75 MS patients were compared using self-rating questionnaires for depressive states, daily activity, and fatigue, as well as serum carnitine levels. A subgroup of patients with low carnitine levels were re-evaluated regarding depression and fatigue after levocarnitine treatment. Depression and fatigue were equally prevalent in MS and NMO and were strongly correlated with one another. Measurement of the serum carnitine levels and the administration of levocarnitine did not appear to be beneficial.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Carnitine; Depression; Fatigue; Levocarnitine; Neuromyelitis optica

Mesh:

Substances:

Year:  2015        PMID: 26004160     DOI: 10.1016/j.jneuroim.2015.05.007

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  13 in total

1.  Evidence for alterations of the glial syncytial function in major depressive disorder.

Authors:  Adriana Medina; Stanley J Watson; William Bunney; Richard M Myers; Alan Schatzberg; Jack Barchas; Huda Akil; Robert C Thompson
Journal:  J Psychiatr Res       Date:  2015-10-23       Impact factor: 4.791

2.  Treatment of Neuromyelitis Optica Spectrum Disorder: Acute, Preventive, and Symptomatic.

Authors:  Remi A Kessler; Maureen A Mealy; Michael Levy
Journal:  Curr Treat Options Neurol       Date:  2016-01       Impact factor: 3.598

Review 3.  Fatigue as a symptom or comorbidity of neurological diseases.

Authors:  Iris-Katharina Penner; Friedemann Paul
Journal:  Nat Rev Neurol       Date:  2017-10-13       Impact factor: 42.937

4.  Fatigue in patients with neuromyelitis optica spectrum disorder and its impact on quality of life.

Authors:  Jin Myoung Seok; Misong Choi; Eun Bin Cho; Hye Lim Lee; Byoung Joon Kim; Kwang Ho Lee; Pamela Song; Eun Yeon Joo; Ju-Hong Min
Journal:  PLoS One       Date:  2017-05-23       Impact factor: 3.240

Review 5.  Efficacy and safety of rituximab in neuromyelitis optica: Review of evidence.

Authors:  Masoud Etemadifar; Mehri Salari; Omid Mirmosayyeb; Mehdi Serati; Roham Nikkhah; Mozhde Askari; Emad Fayyazi
Journal:  J Res Med Sci       Date:  2017-02-16       Impact factor: 1.852

Review 6.  Depressive Syndromes in Autoimmune Disorders of the Nervous System: Prevalence, Etiology, and Influence.

Authors:  Yanjun Liu; Xiangqi Tang
Journal:  Front Psychiatry       Date:  2018-09-25       Impact factor: 4.157

7.  Difference in fatigue and pain between neuromyelitis optica spectrum disorder and multiple sclerosis.

Authors:  Hiroki Masuda; Masahiro Mori; Akiyuki Uzawa; Tomohiko Uchida; Ryohei Ohtani; Satoshi Kuwabara
Journal:  PLoS One       Date:  2020-04-06       Impact factor: 3.240

8.  Association of subcortical structural shapes with fatigue in neuromyelitis optica spectrum disorder.

Authors:  Jin Myoung Seok; Wanzee Cho; Doo-Hwan Son; Jong Hwa Shin; Eun Bin Cho; Sung Tae Kim; Byoung Joon Kim; Joon-Kyung Seong; Ju-Hong Min
Journal:  Sci Rep       Date:  2022-01-28       Impact factor: 4.379

9.  Antiepileptic and Antidepressive Polypharmacy in Patients with Multiple Sclerosis.

Authors:  Georg Anton Giæver Beiske; Trygve Holmøy; Antonie Giæver Beiske; Svein I Johannessen; Cecilie Johannessen Landmark
Journal:  Mult Scler Int       Date:  2015-06-29

10.  Factors associated with fatigue in CNS inflammatory diseases with AQP4 and MOG antibodies.

Authors:  Tianrong Yeo; Giordani Rodrigues Dos Passos; Louwai Muhammed; Rosie Everett; Sandra Reeve; Silvia Messina; Fay Probert; Maria Isabel Leite; Jacqueline Palace
Journal:  Ann Clin Transl Neurol       Date:  2020-03-18       Impact factor: 4.511

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.